An observational study in Biliary Atresia and Prognosis, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Children's Hospital of Fudan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.
Among the 21 studies in Biliary Atresia with a site in China, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2023, is one of 10 observational ones, and was the 14th registered.
78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.
Browse Biliary Atresia studies →7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:
Tongji Hospital · Sites in China
Ages 1 days–3 mo
Children's Hospital of Fudan University · Sites in China
Ages 14 days–90 days
Children's Hospital of Fudan University · Sites in China
Ages up to 3 mo
Weibing Tang · Sites in China
Ages 6 mo–6 yrs
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 1 days–3 mo · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 2
First in 2014; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 120 across 33 observational studies indexed under Biliary Atresia.
Median enrollment 160 across the 11 interventional studies, 200 across the 10 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
Children's Hospital of Fudan University has 5 studies filed under Biliary Atresia — fewer than ten, so there is no comparison to draw.
1 of the studies in Biliary Atresia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940543Nanjing Children's HospitalConstruction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging | 2027-03-10 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Biliary Atresia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.
Kasai portoenterostomy is currently one of the main treatment methods for biliary atresia, but about 30% of children still require liver transplantation even after receiving the surgery. Accurate prognosis will help select the most suitable treatment method for children, but there is currently a lack of effective preoperative predictive indicators. Serum FGF19 has recently been considered a possible preoperative predictive indicator for biliary atresia, but its predictive value has not been confirmed in a large sample and in Asian population, thus the investigators try to further explore the prognostic value of serum FGF19 in children with biliary atresia based on a large sample.
The study enrolled patients meeting following conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Good prognosis: the serum total bilirubin level was less than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery. Poor prognosis: the serum total bilirubin level was higher than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery.
Serum total bilirubin level (umol/l)
The difference of serum total bilirubin level will be measured with ELISA( Enzyme Linked ImmunoSorbent Assay) three months after surgery
Time frame: Three months after surgery
Native liver survival (%)
The difference of native liver survival will be measured according to the follow-up statue one year after surgery
Time frame: One year after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Jun 2026, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Fudan University →